Objective:

To discuss potential vaccines and therapeutics for the Bundibugyo Ebola outbreak.

Key Findings:

• No approved vaccines or therapeutics exist for the Bundibugyo species of Ebola.
• Gilead's remdesivir and two monoclonal antibodies (MBP134 and Maftivimab) were prioritized for testing.
• Testing of Gilead's obeldesivir is also recommended to prevent disease development in exposed individuals.
• Merck's Ervebo vaccine may offer cross-protection but should only be used in clinical trials.

Interpretation:

The WHO's recommendations highlight the urgent need for clinical trials to evaluate potential treatments and vaccines for the current Ebola outbreak.

Limitations:

• Bundibugyo-specific vaccines are not currently available and will take months to develop.
• The effectiveness of existing vaccines against Bundibugyo is not established.

Conclusion:

The WHO is actively seeking to identify and test potential vaccines and therapeutics to address the ongoing Ebola outbreak.